FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
01/05/2025
Back to search
Official data from USPTO
TME PHARMA
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: CombinedOffice: United States
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
30
Latest update
01/05/2025
Trademark type
Combined
Nice classes
1, 5, 42, 44
Filing date
11/03/2022
Registration date
06/25/2024
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
06/25/2024
Last transaction
01/05/2025
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Drawing code
3
Owner type
03
Owner location
DE
Examiner
BULLOFF, TOBY
Current location
FILE REPOSITORY (FRANCONIA)
Mark description
The mark consists of the stylized blue wording 'TME pharma' stacked to the left of a design comprised of a light blue circle containing transparent lines partially surrounded by a light green and blue curved line.
Holders and representatives
Holders
TME Pharma AG
Representatives
Ursula B. Day law firm of Ursula B. Day
Technical classification
Nice Classes
Class 1Class 5Class 42Class 44
Vienna Codes
No Vienna codes available.
Goods and services
Class 1
Chemicals for use in industry and sciencein particular compounds of nucleic acids and derivatives thereof and l-nucleotides and proteins and peptides and derivatives thereofall for use in the production and development of pharmaceuticalsveterinary and biotechnological products;
Class 5
Medicinesmedical preparations and medicines for animalsfor treating cancer and ophthalmological indicationsdiagnostic agents for pharmaceutical use; pharmaceuticals and natural remediesfor treating cancer and ophthalmological indications; pharmaceutical compositionsfor treating cancer and ophthalmological indications; pharmaceutical preparationsfor treating cancer and ophthalmological indications;
Class 42
Science and technology servicesscientific analysis in the field of biotechnologytherapeutics and research and planning services relating to development of pharmaceuticals; medical and pharmacological research services; pharmaceutical research; computer software design; design of databasesdesign of online databases; computer programmingupdatingdesign and rental of computer software for managing medical patient datamedical teaching and interactive medical simulations; providing onlinenon-downloadable computer programs and data networks for managing medical patient datamedical teaching and interactive medical simulations; scientific and technological servicesscientific analysis in the field of biotechnologytherapeutics and research and design relating thereto in the field of genetic engineering; scientific research for medical purposes and for biochemical usescientific contract research; research and development of processessyntheses and devices for the medical sector and research in the fields of chemistrybiologybiophysicsmedicinebiochemistrygeneticsgenetic engineeringbacteriology; scientific experiments and analyses; surveying; chemistry serviceslaboratory research in the field of chemistrybiotechnologymedicine; chemical laboratories; medical laboratory services
Class 44
Medical services in the field of medicine; medical and clinical examinations; pharmaceutical advice;
Publications
History of USPTO decisions and trademark events.
30 publications found
FICS
FINAL DISPOSITION NOTICE SENT TO IB
12/12/2024
FIMP
FINAL DISPOSITION PROCESSED
12/11/2024
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
09/25/2024
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
06/25/2024
R.PR
REGISTERED-PRINCIPAL REGISTER
06/25/2024
OPNR
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
06/10/2024
GPNX
NOTIFICATION PROCESSED BY IB
04/15/2024
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
04/09/2024
PUBO
PUBLISHED FOR OPPOSITION
04/09/2024
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
03/27/2024
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
03/27/2024
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
03/20/2024
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
02/29/2024
XAEC
EXAMINER'S AMENDMENT ENTERED
02/29/2024
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
02/29/2024
GNEA
EXAMINERS AMENDMENT E-MAILED
02/29/2024
CNEA
EXAMINERS AMENDMENT -WRITTEN
02/29/2024
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
02/28/2024
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
02/28/2024
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
02/28/2024
RFNP
REFUSAL PROCESSED BY IB
10/11/2023
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
09/14/2023
RFRR
REFUSAL PROCESSED BY MPU
09/13/2023
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
08/23/2023
CNRT
NON-FINAL ACTION WRITTEN
08/22/2023
DOCK
ASSIGNED TO EXAMINER
08/18/2023
MAFR
APPLICATION FILING RECEIPT MAILED
01/17/2023
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
01/13/2023
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
01/12/2023
Continuous trademark protection
Get notified about every new filing that threatens TME PHARMA or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.